## Phase 2 clinical trial data for Auralin and Novodra Trials
<br>
350 patients for new oral insulin Auralin,half of the patients are being treated with Auralin, and the other 175 being treated with injectable insulin Novodra.
<br>
use HBA1C level change as key metric to determine if Auralin drug is effective enough to reduce blood sugar level for diabetes patients
<br>
<b>patients,treatments, adverse reactions data</b>
<br>
Data schema 
patients columns:

patient_id: the unique identifier for each patient in the Master Patient Index (i.e. patient database) of the pharmaceutical company that is producing Auralin
assigned_sex: the assigned sex of each patient at birth (male or female)
given_name: the given name (i.e. first name) of each patient
surname: the surname (i.e. last name) of each patient
address: the main address for each patient
city: the corresponding city for the main address of each patient
state: the corresponding state for the main address of each patient
zip_code: the corresponding zip code for the main address of each patient
country: the corresponding country for the main address of each patient (all United states for this clinical trial)
contact: phone number and email information for each patient
birthdate: the date of birth of each patient (month/day/year). The inclusion criteria for this clinical trial is age >= 18 (there is no maximum age because diabetes is a growing problem among the elderly population)
weight: the weight of each patient in pounds (lbs)
height: the height of each patient in inches (in)
bmi: the Body Mass Index (BMI) of each patient. BMI is a simple calculation using a person's height and weight. The formula is BMI = kg/m2 where kg is a person's weight in kilograms and m2 is their height in metres squared. A BMI of 25.0 or more is overweight, while the healthy range is 18.5 to 24.9. The inclusion criteria for this clinical trial is 16 >= BMI >= 38.


